GET DAILY SIGNALSNRC Health (NRC) Q3 2026 Earnings Outlook: Tracking Revenue Recovery and TRCV Growth
Key Takeaways
- NRC Health is expected to report its third-quarter 2026 results in early November 2026, following a second quarter that marked a return to year-over-year revenue growth.
- In Q2 2026, revenue rose roughly 4% year over year to $35.4 million, while adjusted earnings per share (EPS) of $0.31 far exceeded a consensus estimate of -$0.15.
- Management guided toward sequential revenue growth in Q3 2026, with adjusted EBITDA margin expected to stay near the 27% level seen in the first half.
- Total Recurring Contract Value (TRCV) — a leading indicator of future subscription revenue — grew 11% year over year to $151.9 million in Q2 2026.
- A large Q1 landmark multi-solution win began generating revenue in Q3, while an anticipated roughly 40% effective tax rate may pressure reported net income.
Earnings Context and Why It Matters
National Research Corporation, which operates as NRC Health, delivers subscription-based healthcare experience and market intelligence software to health systems. Its quarterly earnings are closely watched because nearly 99% of revenue is recurring, making TRCV the clearest signal of future top-line direction. After a challenging 2024 and 2025 marked by elevated client attrition, the company has pivoted toward a refined sales strategy that produced an 86% jump in full-year new sales and five-plus consecutive quarters of TRCV growth. This Q3 2026 report tests whether that momentum can convert into durable, profitable revenue expansion while management absorbs investment costs and a heavier second-half tax burden. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
NRC Health does not provide formal EPS guidance each quarter, so investors lean on management commentary and trend lines. For Q3 2026, leadership has signaled sequential revenue growth, with adjusted EBITDA margin expected to remain roughly in line with the 27% posted during the first half of the year. That reflects timing pressure from the company's annual customer conference, historically held in the third quarter, which raises selling, general, and administrative expenses.
For context, Q2 2026 delivered revenue of $35.39 million (up 3.98% year over year) and adjusted EPS of $0.31, while GAAP results swung to a net loss of $3.3 million, largely due to previously announced accelerated stock vesting and related cash bonuses. Watch for TRCV, which reached $151.9 million in Q2, as well as any commentary on retention and new-sales pipeline. Management also flagged that an effective tax rate near 40% in Q3 and Q4 could compress reported net income relative to prior quarters.
Market Reaction and Investor Sentiment
Sentiment heading into Q3 2026 earnings is cautiously constructive. NRC Health shares advanced about 5% in the session following its July Q2 report, reflecting investor relief that revenue returned to growth and that adjusted results handily beat consensus. Still, lingering concerns remain around competitive disruption following the Qualtrics–Press Ganey acquisition, which closed in May and prompted two active request-for-proposal (RFP) processes to pause for reassessment. Investors will be watching whether pipeline conversion resumes and whether margin guidance for the back half of the year holds up amid elevated operating and tax costs.
Forward Outlook and Key Factors to Monitor
The most important forward indicator remains TRCV. After growing 11% year over year to $151.9 million in Q2 2026, continued sequential expansion would support the view that recognized revenue can keep climbing into 2027.
Investors should also monitor the ramp of the company's large Q1 landmark win. That multi-solution engagement went live with an initial 25 hospitals plus ambulatory sites, with full deployment targeted by year-end and revenue recognition beginning in Q3. A separate rounding-platform purchase from the same customer is expected to launch in the second half of 2027, offering a longer-dated catalyst.
On the cost side, the annual customer conference timing and a roughly 40% effective tax rate are likely to weigh on Q3 and Q4 reported results, even as adjusted EBITDA margin is expected to improve in the fourth quarter as revenue scales and expenses normalize. Finally, watch cross-sell traction: management has noted that about 70% of customers currently buy only one NRC product, a dynamic that frames a meaningful expansion opportunity if the company's AI-enabled offerings and ambient-listening rounding tools continue to gain adoption.
Exploring Tickeron’s AI Screener for Earnings Research
In my own research process, Tickeron’s AI Screener has become a useful companion when preparing for earnings seasons like this one. It lets me quickly filter stocks and ETFs by technical patterns, fundamentals, trends, and AI-driven signals to surface relevant ideas and compare names within the same space. This approach helps refine watchlists efficiently without relying solely on manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NRC's Indicator enters downward trend
The Aroon Indicator for NRC entered a downward trend on October 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 203 similar instances where the Aroon Indicator formed such a pattern. In 176 of the 203 cases the stock moved lower. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for NRC crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 57%.
NRC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on NRC as a result. In 60 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for NRC just turned positive on October 15, 2026. Looking at past instances where NRC's MACD turned positive, the stock continued to rise in 29 of 46 cases over the following month. The odds of a continued upward trend are 63%.
NRC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRC advanced for three days, in 209 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 26 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. NRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRC's P/B Ratio (75.826) is very high in comparison to the industry average of (4.273). NRC's P/E Ratio (93.542) is considerably higher than the industry average of (13.541). Projected Growth (PEG Ratio) (2.150) is also within normal values, averaging (2.133). Dividend Yield (0.029) settles around the average of (0.012) among similar stocks. P/S Ratio (3.460) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of market research services for the healthcare industry
Industry ServicestotheHealthIndustry
Advertisement